Oral oncology最新文献

{"title":"Pain management following transoral robotic surgery for oropharyngeal squamous cell Carcinoma: A systematic review.","authors":"George B Sankar, Ghazal S Daher, Lazaro R Peraza, Eric J Moore, Daniel L Price, Kendall K Tasche, Linda X Yin, Toby N Weingarten, Kathryn M Van Abel","doi":"10.1016/j.oraloncology.2024.107147","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107147","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"107147"},"PeriodicalIF":4.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.","authors":"J M Price, K Garcez, C Hughes, L W Lee, H M Mistry, G Motamedi-Ghahfarokhi, G J Price, C M West, D J Thomson","doi":"10.1016/j.oraloncology.2024.107138","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107138","url":null,"abstract":"<p><strong>Introduction: </strong>Studies reported inferior outcomes when radiotherapy starts >6-8 weeks post-surgery for head and neck squamous cell carcinoma (HNSCC) but are limited due to time variable dichotomization. We assessed the relationship between survival and the time between surgery and radiotherapy as a continuous variable, hypothesising there would be no change in patients' survival at 6-8 weeks post-surgery.</p><p><strong>Methods/materials: </strong>Inclusion criteria: patients with HNSCC who underwent surgery and adjuvant (chemo)radiotherapy, Jan 2014-Dec 2020. A sub-cohort included patients with oral cavity squamous cell carcinoma (OCSCC) treated at the same institution, Jan 2016-Dec 2020. The primary endpoint was overall survival (OS); a multivariable Cox model was fitted. For the OCSCC sub-cohort, the endpoint of interest was progression-free survival (PFS); a multivariable competing risk regression model was fitted.</p><p><strong>Results: </strong>386 patients with HNSCC were included (main cohort). The median time between surgery and radiotherapy was 44 days (IQR: 14 days). Plotting time intervals vs log(hazard) did not demonstrate a threshold time where risk of death increases. The time interval between surgery and radiotherapy was not associated with OS (HR 1.00; 95 % CI 0.99-1.02; p = 0.4). In the sub-cohort of 208 patients with OCSCC, the time interval between surgery and radiotherapy was not associated with increased risk of cancer vs competing events (HR 1.01; 95 % CI 0.99-1.03; p = 0.5).</p><p><strong>Conclusion: </strong>Increasing time interval between surgery and radiotherapy was not associated with inferior survival outcomes. We suggest patients are considered for radiotherapy >6-8 weeks post-surgery and that no threshold is considered for patient selection.</p>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"107138"},"PeriodicalIF":4.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA.","authors":"Ann-Kristin Struckmeier, Martin Gosau, Ralf Smeets","doi":"10.1016/j.oraloncology.2024.107145","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107145","url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) poses a considerable challenge due to its high incidence and mortality rates. Immunotherapy targeting PD-(L)1 emerges as a promising approach for HNSCC, as it has the potential to trigger a broad and long-lasting anti-tumor response. Nevertheless, the effectiveness of immunotherapy encounters hurdles, and only a small proportion of patients benefit, with many eventually experiencing relapse. Consequently, there is a pursuit of strategies to enhance overall treatment outcomes. Understanding the mechanisms driving resistance to PD-(L)1 inhibition and devising strategies to overcome these challenges are vital for advancing more effective treatments. Furthermore, gaining insights into the mechanisms of action and safety profiles of novel combination therapies is critical for their successful adoption in clinical practice. As a result, current research is dedicated to investigating various immunotherapeutic agents beyond the PD-1/PD-L1 axis. This review offers a comprehensive overview of the existing immunotherapy strategies in HNSCC with a focus on TIM-3, TIGIT, LAG-3, and VISTA. The aim is to lay a strong foundation for the continual advancement of therapies for HNSCC.</p>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"107145"},"PeriodicalIF":4.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of race and ethnicity with quality of care among head and neck cancer patients in California.","authors":"Uchechukwu C Megwalu, Yifei Ma, Vasu Divi","doi":"10.1016/j.oraloncology.2024.107144","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107144","url":null,"abstract":"<p><strong>Background: </strong>There are significant racial disparities in head and neck cancer (HNC) outcomes. Racial differences in survival may be explained by differential access to high-quality care. The goal of this study was to evaluate the association of race and ethnicity with the quality of the treating hospital, and receipt of guideline-compliant care among HNC patients.</p><p><strong>Methods: </strong>Retrospective cohort study of data from the California Cancer Registry dataset linked with discharge records and hospital characteristics. The study cohort included adult patients with HNC diagnosed between January 1, 2010, and December 31, 2019. Outcome measures included the quality of treating hospital, and NCCN guideline-compliant care.</p><p><strong>Results: </strong>Black (OR 0.76, 95 % CI 0.67 to 0.85) and Hispanic (OR 0.68, 95 % CI 0.63 to 0.74) patients were less likely to be treated in top-quality hospitals compared with non-Hispanic White patients, after adjusting for demographic, and clinical factors. This association disappeared for Black patients, but persisted for Hispanic patients, after additionally adjusting for socioeconomic status and insurance status. Black patients with advanced-stage disease were less likely to be treated with dual-modality therapy (OR 0.82, 95 % CI 0.70 to 0.96), however, this association disappeared after adjusting for demographic, and clinical factors, and hospital quality.</p><p><strong>Conclusion: </strong>There are significant racial and ethnic disparities in quality of care for patients with HNC. Our findings suggest that differential access to high-quality care may account for some of the racial disparities in HNC survival, and highlight the need for continued investigation into the drivers of racial disparities in HNC outcomes.</p>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"107144"},"PeriodicalIF":4.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Surgical, functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal cancers: A systematic review\".","authors":"Gian Marco Pace, Andrea Costantino, Armando De Virgilio","doi":"10.1016/j.oraloncology.2024.107142","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107142","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"107142"},"PeriodicalIF":4.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Extensive necrosis of the tongue as a very early adverse event of head and neck radiotherapy\".","authors":"Lucas Alves da Mota Santana, Bernardo Ferreira Brasileiro, Rajiv Gandhi Gopalsamy, Gina Délia Roque-Torres, Dalmo Correia-Filho, Lysandro Pinto Borges, Cleverson Luciano Trento, Leandro Napier de Souza","doi":"10.1016/j.oraloncology.2024.107143","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107143","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"107143"},"PeriodicalIF":4.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.","authors":"Shi-Tong Yu, Da Huang, Chengfeng Xiong, Rong Xie, Jichun Yu","doi":"10.1016/j.oraloncology.2024.107140","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107140","url":null,"abstract":"<p><strong>Background: </strong>Locally advanced papillary thyroid carcinoma (PTC) with RET fusion-positive poses significant challenges for surgical resection due to tumor invasion into critical structures. Neoadjuvant targeted therapies are a promising approach to reduce the tumor burden and improve the resectability. Selperctinib, a RET kinase inhibitor, has been approved for the treatment of advanced or metastatic RET-altered thyroid cancer. However, the efficacy of selperctinib as a neoadjuvant treatment for locally advanced RET-altered thyroid cancer is unclear.</p><p><strong>Case presentation: </strong>We report two cases of RET fusion-positive PTC that received neoadjuvant treatment with selperctinib (160 mg twice daily) to reduce the tumor size and enable for radical resection. Tumor sizes were reduced after neoadjuvant treatment with selperctinib. Patients successfully underwent R0 resection with no major surgical complications.</p><p><strong>Conclusion: </strong>Selperctinib isa potential neoadjuvant treatment for PTC with RET fusion-positive.</p>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"107140"},"PeriodicalIF":4.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 10 %-rule debate: A fresh perspective on sentinel lymph node biopsy in OSCC.","authors":"Carlos M Ardila, Pradeep Kumar Yadalam","doi":"10.1016/j.oraloncology.2024.107141","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107141","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"107141"},"PeriodicalIF":4.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months.","authors":"Neil D Almeida, Han Yu, Austin J Iovoli, Mengyu Fang, Tyler V Schrand, Abigail Pepin, Vishal Gupta, Kimberly E Wooten, Michael R Markiewicz, Ryan P McSpadden, Wesley L Hicks, Mark K Farrugia, Anurag K Singh","doi":"10.1016/j.oraloncology.2024.107136","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107136","url":null,"abstract":"<p><strong>Importance: </strong>The role of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement in head and neck cancer (HNC) patients treated with chemoradiation remains controversial and varies by center.</p><p><strong>Objective: </strong>To evaluate the impact of prophylactic PEG tube placement in patients undergoing chemoradiation for HNC PEG tube use for more than 6 months and weight loss.</p><p><strong>Design, setting, and participants: </strong>This single-institution retrospective study included 502 patients with head and neck cancer.</p><p><strong>Exposures: </strong>Concurrent Chemoradiation (CCRT) and prophylactic PEG tube placement.</p><p><strong>Main outcomes and measures: </strong>Univariate analyses were performed to determine risk factors for long term PEG tube and weight loss. Outcomes that were significantly associated with prophylactic PEG were selected for a multivariate analysis. The Kaplan-Meier method was used to estimate survival and the time to PEG removal, with comparisons between groups analyzed by log-rank tests. The global health status score from the EORTC QLQ30 was utilized to assess impact on quality of life.</p><p><strong>Results: </strong>Significantly higher weight loss was seen with the following variables: 1) omitting prophylactic PEG tube (p < 0.00001), 2) younger age (p = 0.0032), and 3) adjuvant CCRT (p = 0.0005). There was significantly higher risk of feeding tube duration longer than 6 months in those who: received prophylactic PEG tube (p < 0.0001) and were older than the median age of 60.8 years (p = 0.0165) on multivariate analysis. Prophylactic PEG tube was not associated with improved global health status, overall survival, or progression-free survival on univariate analysis.</p><p><strong>Conclusions and relevance: </strong>Prophylactic feeding tubes significantly decreased weight loss during treatment. Prophylactic PEG tube and older than median age was significantly associated with higher risk of feeding tube duration longer than 6 months.</p>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"107136"},"PeriodicalIF":4.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Time to treatment for head and neck cancer patients decreased during the early phase of the COVID-19 pandemic\".","authors":"Lucas Alves da Mota Santana, Marina Dos Santos Barreto, Gilmagno Amado Santos, Rajiv Gandhi Gopalsamy, Bernardo Ferreira Brasileiro, Cleverson Luciano Trento, Lysandro Pinto Borges","doi":"10.1016/j.oraloncology.2024.107134","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.107134","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"107134"},"PeriodicalIF":4.0,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}